Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2012.09.008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2014English

Nab-Paclitaxel as Second-Line Treatment in Advanced Gastric Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group

Annals of Gastroenterology
2017English

Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

Gynecologic Oncology
GynecologyOncologyObstetrics
2017English

A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2015English

Nab-Paclitaxel: Potential for the Treatment of Advanced Pancreatic Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

A Phase I Study of Paclitaxel, Topotecan, Cisplatin and Filgrastim in Patients With Newly Diagnosed Advanced Ovarian Epithelial Malignancies: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2007English

Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy